These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 33618009)

  • 21. Serological proteome analysis approach-based identification of ENO1 as a tumor-associated antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21-1 in the detection of non-small cell lung cancer.
    Dai L; Qu Y; Li J; Wang X; Wang K; Wang P; Jiang BH; Zhang J
    Oncotarget; 2017 May; 8(22):36664-36673. PubMed ID: 28456790
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Compensated Interferometry Measures of CYFRA 21-1 Improve Diagnosis of Lung Cancer.
    Kammer MN; Kussrow AK; Webster RL; Chen H; Hoeksema M; Christenson R; Massion PP; Bornhop DJ
    ACS Comb Sci; 2019 Jun; 21(6):465-472. PubMed ID: 31022347
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Angiogenesis Biomarkers May Be Useful in the Management of Patients With Indeterminate Pulmonary Nodules.
    Seder CW; Kubasiak JC; Pithadia R; Basu S; Fhied C; Tarhoni I; Davila E; Alnajjar H; Chmielewski GW; Warren WH; Liptay MJ; Borgia JA
    Ann Thorac Surg; 2015 Aug; 100(2):429-36. PubMed ID: 26138771
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer.
    Lai RS; Hsu HK; Lu JY; Ger LP; Lai NS
    Chest; 1996 Apr; 109(4):995-1000. PubMed ID: 8635383
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of cytokeratin 19 fragment (CYFRA 21-1) as a tumor marker in malignant pleural effusion.
    Lai RS; Chen CC; Lee PC; Lu JY
    Jpn J Clin Oncol; 1999 Sep; 29(9):421-4. PubMed ID: 10563194
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor-derived Autoantibodies Identify Malignant Pulmonary Nodules.
    Lastwika KJ; Kargl J; Zhang Y; Zhu X; Lo E; Shelley D; Ladd JJ; Wu W; Kinahan P; Pipavath SNJ; Randolph TW; Shipley M; Lampe PD; Houghton AM
    Am J Respir Crit Care Med; 2019 May; 199(10):1257-1266. PubMed ID: 30422669
    [No Abstract]   [Full Text] [Related]  

  • 27. Assessment of a Combined Panel of Six Serum Tumor Markers for Lung Cancer.
    Molina R; Marrades RM; Augé JM; Escudero JM; Viñolas N; Reguart N; Ramirez J; Filella X; Molins L; Agustí A
    Am J Respir Crit Care Med; 2016 Feb; 193(4):427-37. PubMed ID: 26465739
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Value of Combined Detection of Cytokines and Tumor Markers in the 
Differential Diagnosis of Benign and Malignant Solitary Pulmonary Nodules].
    Shi J; Liu X; Ming Z; Li W; Lv X; Yang X; Wang Y; Zhang M; Yang S
    Zhongguo Fei Ai Za Zhi; 2021 Jun; 24(6):426-433. PubMed ID: 34157802
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer.
    Pujol JL; Grenier J; Daurès JP; Daver A; Pujol H; Michel FB
    Cancer Res; 1993 Jan; 53(1):61-6. PubMed ID: 7677981
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic value of CYFRA 21-1 and carcinoembryonic antigen in diagnosis of operable lung cancer from benign lung disease.
    Chen F; Li J; Qi X; Qi J
    J Cancer Res Ther; 2018 Jun; 14(Supplement):S400-S404. PubMed ID: 29970696
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas.
    Stieber P; Dienemann H; Schalhorn A; Schmitt UM; Reinmiedl J; Hofmann K; Yamaguchi K
    Anticancer Res; 1999; 19(4A):2673-8. PubMed ID: 10470218
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of tumor markers in the cytological fluid obtained from computed tomography-guided needle aspiration biopsy for the diagnosis of non-small cell lung cancer.
    Hong YJ; Hur J; Lee HJ; Nam JE; Kim YJ; Kim HS; Kim HY; Kim SK; Chang J; Kim JH; Chung KY; Choi BW; Choe KO
    J Thorac Oncol; 2011 Aug; 6(8):1330-5. PubMed ID: 21847061
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Diagnostic value of serum tumor markers in differentiating malignant from benign solitary pulmonary nodules].
    Ni LF; Liu XM
    Beijing Da Xue Xue Bao Yi Xue Ban; 2014 Oct; 46(5):707-10. PubMed ID: 25331391
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The diagnostic value of FDG coincidence imaging combined with serum tumor marker assays for pulmonary lesions].
    Yang JG; Li CL; Gong M; Zou LF
    Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):683-5. PubMed ID: 17274375
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The diagnostic and prognostic value of ProGRP in lung cancer.
    Nisman B; Biran H; Ramu N; Heching N; Barak V; Peretz T
    Anticancer Res; 2009 Nov; 29(11):4827-32. PubMed ID: 20032442
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preoperative diagnosis of malignant pulmonary nodules in lung cancer screening with a radiomics nomogram.
    Liu A; Wang Z; Yang Y; Wang J; Dai X; Wang L; Lu Y; Xue F
    Cancer Commun (Lond); 2020 Jan; 40(1):16-24. PubMed ID: 32125097
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum Protein Markers for the Early Detection of Lung Cancer: A Focus on Autoantibodies.
    Broodman I; Lindemans J; van Sten J; Bischoff R; Luider T
    J Proteome Res; 2017 Jan; 16(1):3-13. PubMed ID: 27769114
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ultrasensitive DNA hypermethylation detection using plasma for early detection of NSCLC: a study in Chinese patients with very small nodules.
    Chen C; Huang X; Yin W; Peng M; Wu F; Wu X; Tang J; Chen M; Wang X; Hulbert A; Brock MV; Liu W; Herman JG; Yu F
    Clin Epigenetics; 2020 Mar; 12(1):39. PubMed ID: 32138766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distinguishing patients with stage I lung cancer versus control individuals using serum mass profiling.
    Hanas JS; Peyton MD; Lerner MR; Lightfoot SA; Deb SJ; Hanas RJ; Vu NT; Kupiec TC; Stowell DE; Brackett DJ; Dubinett SM; Hocker JR
    Cancer Invest; 2014 May; 32(4):136-43. PubMed ID: 24579933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Screening values of carcinoembryonic antigen and cytokeratin 19 fragment for lung cancer in combination with low-dose computed tomography in high-risk populations: Initial and 2-year screening outcomes.
    Triphuridet N; Vidhyarkorn S; Worakitsitisatorn A; Sricharunrat T; Teerayathanakul N; Auewarakul C; Chungklay N; Krongthong W; Luengingkasoot S; Sornsamdang G; Patumanond J; Sritipsukho P
    Lung Cancer; 2018 Aug; 122():243-248. PubMed ID: 30032839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.